KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Current Deferred Revenue (2016 - 2025)

Elevance Health (ELV) has disclosed Current Deferred Revenue for 17 consecutive years, with $1.8 billion as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 2.12% to $1.8 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 billion, a 2.12% increase, with the full-year FY2024 number at $1.5 billion, up 7.56% from a year prior.
  • Current Deferred Revenue was $1.8 billion for Q3 2025 at Elevance Health, up from $1.6 billion in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $4.5 billion in Q2 2023 to a low of $954.0 million in Q3 2021.
  • A 5-year average of $2.0 billion and a median of $1.5 billion in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 359.11% in 2023, then plummeted 66.78% in 2024.
  • Elevance Health's Current Deferred Revenue stood at $1.2 billion in 2021, then fell by 3.56% to $1.1 billion in 2022, then rose by 26.08% to $1.4 billion in 2023, then grew by 7.56% to $1.5 billion in 2024, then increased by 21.42% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ELV's Current Deferred Revenue are $1.8 billion (Q3 2025), $1.6 billion (Q2 2025), and $1.6 billion (Q1 2025).